Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity

Translational Research

Volumn 149, Issue 6, 2007, Pages 317-323

  Lu, Guijing ^a,d   Chiem, Alan ^a   Anuurad, Erdembileg ^a   Havel, Peter J ^a   Pearson, Thomas A ^b   Ormsby, Bernard ^a   Berglund, Lars ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; WAIST HIP RATIO;

EID: 34249279798     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.12.008     Document Type: Article

References (42)

1. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
2. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
3. Combs T.P., Berg A.H., Obici S., Scherer P.E., and Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108 (2001) 1875-1881
4. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53 suppl 1 (2004) S143-S151
5. Combs T.P., Berg A.H., Rajala M.W., Klebanov S., Iyengar P., Jimenez-Chillaron J.C., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52 (2003) 268-276
6. Pischon T., Girman C.J., Rifai N., Hotamisligil G.S., and Rimm E.B. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 81 (2005) 780-786
7. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
8. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes. In press.
9. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
10. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
11. Okamoto Y., Kihara S., Funahashi T., Matsuzawa Y., and Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 110 (2006) 267-278
12. Duncan B.B., Schmidt M.I., Pankow J.S., Bang H., Couper D., Ballantyne C.M., et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53 (2004) 2473-2478
13. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
14. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
15. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
16. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
17. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 10 (2002) 1104-1110
18. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
19. Pilz S., Mangge H., Wellnitz B., Seelhorst U., Winkelmann B.R., Tiran B., et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 91 (2006) 4277-4286
20. Faraj M., Havel P.J., Phelis S., Blank D., Sniderman A.D., and Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88 (2003) 1594-1602
21. Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 200-206
22. Carnethon M.R., Loria C.M., Hill J.O., Sidney S., Savage P.J., and Liu K. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 27 (2004) 2707-2715
23. Goodpaster B.H., Krishnaswami S., Harris T.B., Katsiaras A., Kritchevsky S.B., Simonsick E.M., et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 165 (2005) 777-783
24. Paultre F., Pearson T.A., Weil H.F., Tuck C.H., Myerson M., Rubin J., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
25. Jiang X.C., Paultre F., Pearson T.A., Reed R.G., Francis C.K., Lin M., et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 20 (2000) 2614-2618
26. Anuurad E., Rubin J., Lu G., Pearson T.A., Holleran S., Ramakrishnan R., et al. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res 47 (2006) 2475-2481
27. Rubin J., Kim H.J., Pearson T.A., Holleran S., Ramakrishnan R., and Berglund L. Apoa size and PNR explain African American-Caucasian differences in allele-specific apoa levels for small but not large apoa. J Lipid Res 47 (2006) 982-989
28. Tuck C.H., Holleran S., and Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 17 (1997) 1822-1829
29. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
30. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
31. Adler A.I., Levy J.C., Matthews D.R., Stratton I.M., Hines G., and Holman R.R. Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 22 (2005) 306-311
32. Miller M., Mead L.A., Kwiterovich Jr. P.O., and Pearson T.A. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 65 (1990) 1-5
33. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
34. Hulver M.W., Saleh O., MacDonald K.G., Pories W.J., and Barakat H.A. Ethnic differences in adiponectin levels. Metabolism 53 (2004) 1-3
35. Retnakaran R., Hanley A.J., Raif N., Connelly P.W., Sermer M., and Zinman B. Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration. Diabet Med 21 (2004) 388-392
36. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
37. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulat 103 (2001) 1057-1063
38. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulat 105 (2002) 2893-2898
39. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
40. Paultre F., Tuck C.H., Boden-Albala B., Kargman D.E., Todd E., Jones J., et al. Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 22 (2002) 141-146
41. Anuurad E., Lu G., Rubin J., Pearson T.A., and Berglund L. Apo E genotype affect allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset study. J Lipid Res 48 (2007) 693-698
42. Rodriguez C., Pablos-Mendez A., Palmas W., Lantigua R., Mayeux R., and Berglund L. Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and Non-Hispanic Caucasians > or =65 years of age living in New York City. Am J Cardiol 89 (2002) 178-183